How do these popular medications impact endometriosis treatment?
By: Dr. Mallory A. Stuparich, Endometriosis Surgeon, Orange County, Southern California
Glucagon-Like Peptide-1 receptor agonists (GLP-1 RAs), including medications like semaglutide, exenatide, and liraglutide, are emerging as important therapies beyond their original use for type 2 diabetes and obesity—especially within gynecology and reproductive medicine. Recent peer-reviewed research highlights intriguing connections between GLP-1RAs and endometrial conditions, with evolving evidence about their possible implications for endometriosis and related disorders.[1][2]
What Are GLP-1 Agonists?
GLP-1 agonists mimic glucagon-like peptide-1, a hormone that stimulates insulin secretion while suppressing appetite. When used for weight management, these drugs demonstrate a significant impact on metabolic health—an important consideration for endometriosis patients, given the link between obesity, systemic inflammation, and hormone changes.[2][1]
GLP-1 Agonists and Gynecologic Health
In gynecology, GLP-1 agonists have been most extensively studied in the context of polycystic ovarian syndrome (PCOS) and endometrial hyperplasia. Human and animal studies have shown that GLP-1RAs may improve ovarian function, promote menstrual regularity, and reduce inflammation in reproductive tissues. The anti-inflammatory and anti-fibrotic effects of GLP-1RAs are particularly important, as chronic inflammation and fibrosis are central to the progression of endometriosis.[3][4][5][1]
Emerging Connections: Endometriosis and GLP-1 Agonists
Although specific randomized controlled trials studying GLP-1 agonists for endometriosis are lacking, a few foundational studies have highlighted compelling mechanisms:
- GLP-1 and related hormones appear reduced in the peritoneal fluid of women with endometriosis.[5]
- Laboratory and animal data suggest GLP-1RAs may help decrease cell growth and fibrosis in endometrial tissue models—processes that are central to endometriosis.[3]
- GLP-1RAs promote autophagy, a cellular recycling process, which may inhibit pathological tissue proliferation and chronic inflammation implicated in endometriosis.[6][3]
Weight Loss, Hormonal Modulation, and Endometriosis
Because weight loss and metabolic health positively affect both pain and symptom burden in endometriosis, GLP-1 agonists may provide indirect benefits by reducing adiposity and modulating inflammatory pathways.[2]
A novel area of research explores the combination of GLP-1RA (semaglutide) with progestins in hormone-sensitive tissue models. This approach demonstrated synergistic reductions in cell viability and upregulation of hormone receptors, indicating potential therapeutic cross-talk between metabolic and hormonal treatments.[7]
Key Takeaways for Patients
- GLP-1 agonists are not currently approved to treat endometriosis directly, but mounting evidence points toward benefits in managing weight, metabolic inflammation, and potentially endometrial pathology—a critical factor in multidisciplinary endometriosis care.[1][2]
- Ongoing research continues to clarify their role in gynecologic health, including possible effects on tissue repair mechanisms and inflammatory processes linked to endometriosis.
Patients interested in GLP-1 receptor agonists can consult their specialist team at ESSI to discuss appropriate, evidence-based strategies as part of a comprehensive, patient-centric care plan.
References:
- https://pubmed.ncbi.nlm.nih.gov/40183300/
- https://pubmed.ncbi.nlm.nih.gov/39116625/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11782050/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12504844/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9499521/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11489137/
- https://pubmed.ncbi.nlm.nih.gov/40002193/
- https://pubmed.ncbi.nlm.nih.gov/36944434/
